The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways

Lignende værker

• sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways
  af: Kim, Boh-Ram, et al.
  Udgivet: (2015)
• The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression
  af: Park, Mi Sun, et al.
  Udgivet: (2014)
• mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
  af: Dodd, Kayleigh M., et al.
  Udgivet: (2014)
• Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors
  af: Falcon, Beverly L., et al.
  Udgivet: (2011)
• mTORC1 and mTORC2 coordinate early NK cell development by differentially inducing E4BP4 and T-bet
  af: Li, Dan, et al.
  Udgivet: (2021)